New nano drug candidate kills invasive breast cancer cells

New nano drug candidate kills invasive breast cancer cells

Let’s Start this Interesting Article Shared on

ARKANSAS: Researchers at the University of Arkansas have developed a nano-drug candidate that kills triple-negative breast cancer cells.
Triple-negative breast cancer is one of the most aggressive and fatal types of breast cancer. The research will help physicians directly target breast cancer cells while avoiding the adverse and toxic side effects of chemotherapy.
The study was published in the latest issue of the journal – Advanced Medical Sciences.
Researchers led by Assistant Professor Hassan Bayawi in the Department of Chemistry and Biochemistry combined a new class of nanomaterials called metal-organic frameworks with ligands of a previously developed photodynamic medical drug to create nano-porous materials, which target and Kills tumor cells without causing toxicity to normal cells.
The metal-organic framework is an emerging class of nanomaterials designed for targeted drug delivery. Ligands are molecules that bind to other molecules.
“With the exception of skin cancer, breast cancer is the most common form of cancer in American women. As we know, thousands of women die each year from breast cancer. Patients with triple-negative cells due to the toxic side Are particularly vulnerable. The only approved treatment effects for this type of cancer, “Beyazvi said.
“We have solved this problem by developing a co-formulation that targets cancer cells and has no effect on healthy cells,” said Beyajvi.
Researchers in Beyzavi’s laboratory focused on developing new, targeted photodynamic therapy drugs. As an alternative to chemotherapy – and with significantly fewer side effects – targeted photodynamic therapy, or PDT, is a non-invasive approach that relies on a light sensor that, upon irradiation by light, generates the so-called toxic reactive oxygen species Which does kill cancer cells.
In recent years, PDT has gained attention due to its ability to treat tumors without surgery, chemotherapy or radiation.
BYZV’s laboratory has specialized in integrating metal-organic frameworks such as nanomaterials, with PDT and others and therapies. Metal – organic structures greatly enhance the effectiveness of PDT.
Yoshi Sakamaki, a doctoral student from Beyzvi’s Laboratory, prepared nanometallions and then bio-conjugated them to form nanoporous materials with a PDT drug ligand that targeted and killed tumor cells with special toxicity to normal cells.
In addition to cancer treatment, this novel drug delivery system can also be used with magnetic resonance imaging (MRI) or fluorescence imaging, which can track the drug in the body and monitor the progress of cancer treatment.
This collaborative project also includes contributions from one of the research groups U through Analytical Chemistry Professor Julie Stenken; Yuchun Do, Associate Professor of Biological Sciences and Jin-woo Kim, Professor of Biological and Agricultural Engineering.
The American Cancer Society estimated 268,600 new cases of invasive breast cancer and 41,760 deaths in 2019. Currently, there are more than 3.1 million breast cancer survivors in the United States.
Since 2007, breast cancer mortality has remained stable in women under 50, but has continued to decrease in older women. This deficiency is believed to be the result of earlier detection and better treatment.
Triple-negative breast cancer is aggressive and lacks estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2, meaning it cannot be seen with receptor-targeted therapy. It is difficult to treat with current chemotherapy and often requires surgery as it quickly metastasis throughout the body.
Cytotoxic chemotherapy is the only accepted treatment for this type of breast cancer. More than 80 percent of women suffering from triple-negative breast cancer are treated with chemotherapy drugs, including anthracycline, such as doxorubicin, which can cause serious side effects of cardiotoxicity.
In addition, chemotherapy treatment of breast cancer cell lines using 5-Fu, cisplatin, paclitaxel, doxorubicin, or etoposide has shown multi-drug resistance.


Leave a Reply

Your email address will not be published. Required fields are marked *